{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-244711","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2022-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.124823+00:00","generated_at":"2026-06-23T09:42:07.307485+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nurix appoints Edward C. Saltzman to board of directors","bullets":["Appointed effective Sept 12, 2022 as Class II director with term through 2025 annual meeting.","Received initial option for 50,000 shares vesting over 3 years; annual option of 25,000 shares.","Will serve on Compensation Committee and Development Advisory Committee.","Saltzman has over 30 years biopharma strategy experience, currently Head of Biotech Strategy at Lumanity.","Founder of Defined Health, sold to Cello Health; brings strategic development expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-244711","json":"https://secwatch.observer/filing/0001193125-22-244711.json","markdown":"https://secwatch.observer/filing/0001193125-22-244711.md","text":"https://secwatch.observer/filing/0001193125-22-244711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000119312522244711/0001193125-22-244711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000119312522244711/d408311d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:42:07.307485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eec074c544","claim":"Edward C. Saltzman was appointed as director at Nurix Therapeutics, Inc..","evidence_excerpt":"On September 12, 2022, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Edward C. Saltzman to serve as a director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”) and the Development Advisory Committee of the Board (the “Development Advisory Committee”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000119312522244711/0001193125-22-244711-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}